ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / AGMB
TRXB (48) FENC (33) IRLA (34) TECX (30) ⌘ Pro Terminal →

AgomAb Therapeutics NV (AGMB) — RQD Stock Rating Cockpit

$6.72 -10.28% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $6.58

AgomAb Therapeutics NV (AGMB) carries a Roarable Rating of D (Sell) with 45/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $368.9M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on AGMB Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is AGMB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, AgomAb Therapeutics NV (NASDAQ: AGMB) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $6.72 (-10.28% 1D, market cap $368.9M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, AGMB ranks #366 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does AGMB compare to TRXB and FENC in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), AGMB carries a Roarable D (45/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, TRXB (TRex Bio Inc.) holds a D grade (48/100 RQD, P/E N/A, ROIC —, cap $377.1M) and FENC (Fennec Pharmaceuticals Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -25.9%, cap $358.7M). Among the 5-stock peer group, AGMB leads on earnings multiple (N/A) while FENC leads on capital efficiency (-25.9% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for AGMB?
▼

For AgomAb Therapeutics NV (AGMB), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #366 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $6.58 (-2.04%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0.3% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (45/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.3% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D
025507510045
JEV AI Jury Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D+
Cash (12)Whales (3)SEC (13)Macro (8)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE-5.8% Base Target
$19 Bull$6 Base$5 Bear
📬 FREE AGMB RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for AGMB)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (45/100 Composite)
🔍 WHY AGMB SCORES 45/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (29% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (27% of score)

SEC XBRL Trailing 12 Months: 0.3% FCF Margin ($10.3M FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
53
Grade C-$8.81-0.9% Next Q
Q2 (-2Q)
50
Grade C-$8.73-3.8% Next Q
Q3 (-1Q)
48
Grade D$8.40-20% Next Q
Current
45
Grade D$6.72-6.3% Hist 90D α
Trajectory: C- (53) → D (45)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a AGMB Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While AGMB currently carries a cautious 45/100 (D) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($10.71) and Max Pain ($7.06) forces dealer call-delta covering toward $18.71.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $AGMB• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “AGMB Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”
YES 45%NO 55%Trade / Inspect Odds →
RSI-14 MOMENTUMNEUTRAL RANGE
32.730 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
3.80>3.0 Fortress Safe
PIOTROSKI F-SCOREHIGH QUALITY (7–9)
7 / 99-Pt Accounting
52-WEEK LASER RANGE2% OF RANGE
L: $7$6.72H: $18
1. Money & Cash Health● MIXED
Are profits real cash in the bank?

Decent core business (steady margins), though cash flow growth is moderate rather than explosive right now.

Factor Grade: C-RQD 12 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 12 / 40
3. Hidden Risks & Market Weather● WARNING
SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: D+RQD 21 / 40
MULTI-MODEL JEV QUANT JURY DELIBERATION

JEV AI Jury Split (Battleground) on AGMB

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
NEUTRAL (60)

14.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
NEUTRAL (65)

Altman-Z 4.20 and Piotroski 7/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (33)

12/40 institutional & smart-money positioning score with 8/20 macro alignment.

Bull Case: Why Buyers Like AGMB
  • ✓Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring AGMB)

  • ✓Walkthrough of AGMB's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
AGMB // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -44.51%🛡️ HOLDING TREND SUPPORT
2026-11-03O $7.95H $7.95L $6.72C $6.72VOL 197.8K
RES: $15.42SUP: $6.48SMA50: $10.71SMA200: $12.06
$18.60$15.35$12.10$8.85$5.60RES $15.42SUP $6.48$6.722026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

AGMB Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 AGMB Butterfly Map → + Track AGMB →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on AGMB today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for AGMB. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for AGMB today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (AGMB)

Health Care Rank #366 of 1016 ⚔️ TRXB vs AGMB Full Matrix →

1. Head-to-Head Health Care Peer Comparison (AGMB vs. TRXB, FENC, IRLA, TECX)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, AgomAb Therapeutics NV (AGMB) ranks #366 by composite RQD confidence (45/100, grade D) and #488 by equity capitalization ($368.9M). Within this direct 5-issuer industry benchmark cohort, AGMB leads on earnings valuation at N/A trailing P/E, while FENC leads on capital efficiency and profitability with -25.9% ROIC and — gross margin. TRXB currently holds the highest overall quantitative score in the immediate peer group at 48/100 (D) compared with AGMB at 45/100 (D).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
AGMB ACTIVE
AgomAb Therapeutics NV
D 45/100 — — — -10.28% $368.9M Benchmark Subject
TRXB
TRex Bio Inc.
D 48/100 — — — -0.73% $377.1M /trxb-vs-agmb →
FENC
Fennec Pharmaceuticals Inc.
E 33/100 — — -25.9% +2.93% $358.7M /fenc-vs-agmb →
IRLA
IRulya Therapeutics Inc.
E 34/100 — — -35.0% +1.82% $357.2M /irla-vs-agmb →
TECX
Tectonic Therapeutic Inc.
E 30/100 — — -35.0% -4.04% $386.7M /tecx-vs-agmb →

2. AGMB Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

AgomAb Therapeutics NV (AGMB) operates in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care) with an equity capitalization of $368.9M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. AGMB Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is AGMB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, AgomAb Therapeutics NV (NASDAQ: AGMB) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $6.72 (-10.28% 1D, market cap $368.9M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, AGMB ranks #366 in composite RQD confidence.

How does AGMB compare to TRXB and FENC in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), AGMB carries a Roarable D (45/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, TRXB (TRex Bio Inc.) holds a D grade (48/100 RQD, P/E N/A, ROIC —, cap $377.1M) and FENC (Fennec Pharmaceuticals Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -25.9%, cap $358.7M). Among the 5-stock peer group, AGMB leads on earnings multiple (N/A) while FENC leads on capital efficiency (-25.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for AGMB?

For AgomAb Therapeutics NV (AGMB), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #366 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is AGMB trading relative to its 50-day, 200-day, and 52-week technical levels?

AGMB last traded at $6.72 (-10.28% on volume of 105,636 shares), positioning the stock -37.25% below its 50-day simple moving average ($10.71) and -44.28% below its 200-day simple moving average ($12.06). Across its 52-week range of $6.61 to $17.82, AGMB sits at the 1.0% percentile with a 14-day RSI of 32.7 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($5.88 to $7.56).

Direct Sub-Reports: AGMB RQD Cockpit AGMB 12M Forecast AGMB Earnings & Move AGMB Dividends & DRIP AGMB Insiders & 13F AGMB Whale Options AGMB Profit Sankey AGMB News & Why
ROARABLE RATING BRIEF • RQD 45/100 (D) ✓ SEC XBRL & RQD VERIFIED

AGMB — AgomAb Therapeutics NV: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2026-11-03

1. Roarable Rating Brief: What This Means to a Prospective Investor

AgomAb Therapeutics NV (AGMB) earns a live Roarable RQD composite score of 45/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $6.72 (-10.28% 1D, market capitalization $368.9M).

  • Fundamental Cash Engine (12/20): Anchored by return on invested capital (ROIC) of —, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (13/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (8/20) + Forensic Balance Sheet (9/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of N/A, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

AgomAb Therapeutics NV (AGMB) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Biological Products (No Diagnostic Substances) industry..4B.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D • RQD 45/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 12/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $6.61 – $17.82 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies, sector correlations, and second-order bottlenecks are therefore — The only sector-level context is the Health Care classification and the Biotechnology: Biological Products industry label, with a beta of 1.0 per the market data.

  • Key Question #1: Can AGMB sustain or expand its — operating margin and — ROIC against Biotechnology: Biological Products (No Diagnostic Substances) peers over the next 4 quarters?
  • Key Question #2: Will free cash flow conversion (— FCF yield) strengthen balance-sheet liquidity (Altman Z-Score N/A) toward the $17.82 52-week high?
  • Key Question #3: How sensitive is AGMB's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

AGMB Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for AgomAb Therapeutics NV (AGMB) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to AGMB Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

AGMB Bull vs. Bear Conversation Board — What's Your Call at $6.72?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON AGMB 🐻 33% BEARISH CONVICTION
1. Pick Your Side on AGMB:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
AL AlphaFlow_Cap RQD DEBATE OPENER • Verified $100K Arena Trader 🐂 BULLISH 🎯 Target: $8.91 (+19.0%)
📌 Pinned Debate

Piotroski F-Score of 6/9 and Debt/Equity of 0.5 indicate a comparatively sound balance sheet, and recent director share purchases are d

Don't sleep on AGMB's setup in Health Care. Piotroski F-Score of 6/9 and Debt/Equity of 0.5 indicate a comparatively sound balance sheet, and recent director share purchases are disclosed in the news feed.. Beta of 1.0 means it moves fast when momentum turns, and the 5-pillar RQD gauge (45/100) backs up the fundamental quality.

SectorRotator 🐂 BULL

@RiskArb_Desk Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Biological Products (No Diagnostic Substances). If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.

RI RiskArb_Desk RQD DEBATE OPENER • Hedged Event Driven 🐻 BEARISH 🎯 Target: $6.07 (-19.0%)
Spot @ $7.49

Reported ROIC and FCF yield are both 0%, the RQD rating is 45 (D), and institutional flow scores only 3/20.

Here is the bear case nobody on the bull side wants to address on AGMB: Reported ROIC and FCF yield are both 0%, the RQD rating is 45 (D), and institutional flow scores only 3/20.. At current EV/EBITDA multiples, even a small guidance miss in Biotechnology: Biological Products (No Diagnostic Substances) triggers a 12-15% air pocket.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%